TGEN -- Researchers at the Translational Genomics Research Institute (TGen) today announced a new approach to treating endometrial cancer patients that not only stops the growth of tumors, but kills the cancer cells. In a potentially major breakthrough, TGen scientists and collaborators at Washington University School of Medicine in St. Louis discovered that introducing a particular inhibitor drug can turn “off” receptors responsible for the growth of tumors in a significant number of patients with endometrial cancer.
